CanSino Biologics Returns to Profitability in 2025 as Vaccine Portfolio Drives Growth

CanSino Biologics Inc. has reported a return to profitability in its 2025 annual results, supported by steady growth in its commercial vaccine portfolio and continued progress in product development and international expansion.

The company posted total revenue of approximately RMB 1.068 billion, marking a 26.18 per cent year-on-year increase. Net profit attributable to shareholders reached RMB 27.9 million, signalling a turnaround from previous losses and reflecting improved operational stability.

Growth was primarily driven by the company’s core vaccine products. Its quadrivalent meningococcal conjugate vaccine, Menhycia, maintained consistent revenue expansion, while the 13-valent pneumococcal conjugate vaccine, iPneucia, gained traction following its market launch. The strengthening of routine vaccine sales has contributed to a more balanced revenue mix and enhanced earnings visibility.

Beyond immediate performance, CanSinoBIO continues to advance a diversified pipeline aimed at sustaining long-term growth. A key development includes regulatory approval to expand the eligible age group for Menhycia, broadening its commercial reach. Meanwhile, its diphtheria, tetanus and acellular pertussis (DTcP) vaccine for infants has been included in China’s priority review pathway, potentially accelerating its route to market.

The company’s research and development strategy remains central to its growth outlook. Backed by an experienced global team, CanSinoBIO has built multiple technology platforms spanning viral vectors, mRNA vaccines and protein design, supporting ongoing innovation in multivalent and combination vaccines.

Internationally, the company is accelerating expansion efforts. Its manufacturing facility recently secured PIC/S GMP certification from Malaysia’s National Pharmaceutical Regulatory Agency, strengthening its ability to access global markets. With additional overseas registrations and partnerships in place, CanSinoBIO is increasingly leveraging technology transfer and localized production models to expand its global footprint.

The results come amid a supportive policy environment in China, where biopharmaceuticals have been identified as a strategic growth sector, positioning CanSinoBIO for continued development.